Treatment with serlopitant helps lessen pruritus associated with mild-to-moderate psoriasis, results of a phase II trial have shown. This supports the continued development of serlopitant for this condition.
The oral TYK2/JAK1 inhibitor PF-06700841 appears to be effective in the treatment of patients with moderate-to-severe plaque psoriasis, with a tolerable safety profile, according to the results of a phase IIa study.
Predictive models that include blood inflammatory proteins such as interleukins (IL) 17A and 17C may help gauge the clinical response of psoriasis patients to tofacitinib and etanercept, a new study has shown.
A bidirectional association exists between alopecia areata (AA) and major depressive disorder (MDD) among probands and unaffected siblings, reveals a study. This suggests that shared familial mechanisms tend to cause AA and MDD.
Treatment with photodynamic therapy (PDT) plus aminolevulinic acid (ALA) appears to be effective for some cases of cutaneous squamous cell carcinoma in situ (SCCis), suggests a recent study. In addition, anatomic location, tumour diameter and ALA incubation time contribute to the effectiveness of the combined therapy.
When it comes to protection against ultraviolet radiation–induced erythema and sunburn, sunscreen with sun protection factor (SPF) 100+ is significantly better than that with SPF 50+ in actual use at the beach, a recent study has shown.